Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 13
2003 18
2004 10
2005 22
2006 32
2007 26
2008 25
2009 42
2010 40
2011 31
2012 27
2013 34
2014 39
2015 44
2016 44
2017 44
2018 43
2019 50
2020 40
2021 39
2022 39
2023 6
Text availability
Article attribute
Article type
Publication date

Search Results

600 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB, Kido A. Yang BB, et al. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. ...As a resul …
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases i …
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.
Cerchione C, Nappi D, Martinelli G. Cerchione C, et al. Support Care Cancer. 2021 Nov;29(11):6973-6980. doi: 10.1007/s00520-021-06266-x. Epub 2021 May 14. Support Care Cancer. 2021. PMID: 33990881 Free PMC article. Review.
Filgrastim is a human recombinant subcutaneous preparation of G-CSF, largely adopted in hematological supportive care as "on demand" (or secondary) prophylaxis to recovery from neutropenia and its infectious consequences during anti-myeloma treatment. On the contrary, pegfilgr …
Filgrastim is a human recombinant subcutaneous preparation of G-CSF, largely adopted in hematological supportive care as "on demand" (or sec …
LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. BioDrugs. 2019. PMID: 30887256 Review.
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to be approved in the EU. ...The tolerability and safety profile of and the incidence of anti-drug antibodies with LA-EP2006 were similar to tho …
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to b …
Pegfilgrastim.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012. Drugs. 2002. PMID: 12010086 Review.
Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count increases. ...Moreover, the mean duration of grade 4 neutropenia in cycles 2 to 4 of chemotherapy was significantly lower in recipients of pegfilgrastim th …
Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count increases. ...Moreover …
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Blayney DW, Mohanlal R, Adamchuk H, Kirtbaya DV, Chen M, Du L, Ogenstad S, Ginn G, Huang L, Zhang Q. Blayney DW, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2145446. doi: 10.1001/jamanetworkopen.2021.45446. JAMA Netw Open. 2022. PMID: 35084480 Free PMC article. Clinical Trial.
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy to pegfilgrastim for the prevention of CIN, with better safety and a better immunosuppressive profile. Plinabulin's same-day dosing …
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy …
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. Kirshner JJ, et al. Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16. Support Care Cancer. 2018. PMID: 29147854 Free PMC article. Clinical Trial.
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. ...The prima …
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluat …
Pegfilgrastim.
Willis F, Pettengell R. Willis F, et al. Expert Opin Biol Ther. 2002 Dec;2(8):985-92. doi: 10.1517/14712598.2.8.985. Expert Opin Biol Ther. 2002. PMID: 12517276 Review.
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy induced neutropenia. Pegfilgrastim provides clinical and quality of life benefits for patients as a result of its once per cycle admini …
Single dose pegfilgrastim has been shown to be as safe and effective as daily filgrastim in reducing the incidence of chemotherapy in …
Pegfilgrastim-induced large vessel vasculitis.
Saito H, Suda T, Oishi N, Matsushita E. Saito H, et al. BMJ Case Rep. 2021 Jun 2;14(6):e243757. doi: 10.1136/bcr-2021-243757. BMJ Case Rep. 2021. PMID: 34083201 No abstract available.
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Blayney DW, Zhang Q, Feng J, Zhao Y, Bondarenko I, Vynnychenko I, Kovalenko N, Nair S, Ibrahim E, Udovista DP, Mohanlal R, Ogenstad S, Ette E, Du L, Huang L, Shi YK. Blayney DW, et al. JAMA Oncol. 2020 Nov 1;6(11):e204429. doi: 10.1001/jamaoncol.2020.4429. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 32970104 Free PMC article. Clinical Trial.
IMPORTANCE: Plinabulin is a novel, non-granulocyte colony-stimulating factor (GCSF) small molecule with both anticancer and neutropenia-prevention effects. OBJECTIVE: To assess the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of c …
IMPORTANCE: Plinabulin is a novel, non-granulocyte colony-stimulating factor (GCSF) small molecule with both anticancer and neutropenia-prev …
Pegfilgrastim-induced hyperleukocytosis.
Snyder RL, Stringham DJ. Snyder RL, et al. Ann Pharmacother. 2007 Sep;41(9):1524-30. doi: 10.1345/aph.1K093. Epub 2007 Jul 31. Ann Pharmacother. 2007. PMID: 17666580
Chemotherapy was delayed until the WBC count had fallen to 35.2 x 10(3)/microL (ANC 28.9 x 10(3)/microL). No sequelae from this adverse effect occurred. DISCUSSION: Pegfilgrastim has unique saturable neutrophil receptor-mediated clearance, the ability for self-regul …
Chemotherapy was delayed until the WBC count had fallen to 35.2 x 10(3)/microL (ANC 28.9 x 10(3)/microL). No sequelae from this adverse …
600 results